
Keywords: asimadoline; atopic dermatitis; emerging agents; fezakinumab; hypocholrous acid; omiganan; secukinumab; tapinarof; AD; atopic dermatitis; AE; adverse effect; AhR; aryl hydrocarbon receptor; AMP; antimicrobial peptide; EFA; essential fatty acids; HOCl; hyp